This study assessed adherence to prolonged-release tacrolimus (PR-T)-based immunosuppression during routine maintenance of renal transplant recipients in Germany.
During the 18-month observation period, data were recorded at baseline (Visit [V] 1), and at 6 (V2), 12 (V3), and 18 (V4) months (±2 weeks) postbaseline. At each visit, the following parameters were assessed: the laboratory parameters hemoglobin, serum creatinine, urine protein, and urine albumin; prolonged-release tacrolimus dose and trough levels; concomitant medication; rejection episodes and graft survival; dialysis dependence; vital signs (blood pressure and heart rate); and investigator/nurse assessment of adherence to prolongedrelease tacrolimus over the previous 4 weeks (rated "good," "moderate," or "poor"). Patients could also use ProMate, an electronic device that records the time of blister insertion and, thereby, adherence.
The Basel Assessment of Adherence with Immunosuppressive
Medication Scale (BAASIS © ) was completed at V1 and V4. 14 BAASIS sum scores were also evaluated. If any one of the four BAASIS questions was answered with "yes," points (range 1-5) were allocated depending on the frequency of self-reported nonadherence. For the response "once a month," 1 point was assigned, 2 points for "every 2 weeks," 3 for "every week," 4 for "more than once a week," and 5
points for "every day." Thus, sum scores ranged between 0 (excellent adherence) and 20 (high nonadherence).
Investigator rating of overall effectiveness and tolerability of prolonged-release tacrolimus (based on a five-point rating scale, ranging from "very good" to "very poor"), assessment of patient satisfaction with therapy ("very satisfied," "satisfied," and "not satisfied"), and patient and graft survival were assessed at V4, or where applicable, at the time of premature study termination.
Adverse drug reactions (ADRs) were continuously monitored and were coded in accordance with the Medical Dictionary for Regulatory Activities (MedDRA ® , Version 16.1, English).
Target tacrolimus trough levels were defined by treating physicians on an individual patient basis.
| Endpoints
The primary variable was a composite at V4 of three components:
BAASIS outcomes; investigator rating of adherence; and tacrolimus blood target levels (Table 1 ). 14 A single tacrolimus blood level value outside the predefined target range (set by investigators for each individual patient) was regarded as nonadherence. Patients were considered nonadherent for the composite primary variable if nonadherence was evident for at least one of the components.
Secondary variables included analyses of individual BAASIS com-
ponents and sum scores, patient rating of adherence with the aid of the visual analog scale (VAS) (ranging from 0% = completely nonadherent, to 100% = fully adherent), patient and graft survival, rejection episodes, renal function and vital signs, investigator rating of the overall effectiveness and tolerability of prolonged-release tacrolimus at V4 (based on a five-point rating scale, ranging from "very good" to "very poor"), and assessment of patient satisfaction with therapy at V4
("very satisfied," "satisfied," and "not satisfied.")
| Statistical analysis
It was planned to enroll 150 patients. prolonged-release tacrolimus (n = 6, 3.9%), ADR (n = 2, 1.3%), lost to follow-up (n = 6, 3.9%), and "other" (n = 7, 4.6%). The mean (SD) observational period was 538 (102) days, considering only patients with data recordings after V1 (n = 144).
| RESULTS

| Patient disposition and baseline characteristics
| Tacrolimus dose and trough levels
During the study, mean daily tacrolimus dose declined from 0.059 to 0.051 mg/kg at V1 and V4, respectively ( For patients with valid data at V4, investigators rated adherence in two patients (1.5%) as "poor," and in 113 (85.6%) and 17 (12.9%) as "good" and "moderate," respectively; the remaining 21 patients could not be assessed at V4. At V1, ratings were "good" for 129 (84.3%) and "moderate" for 24 (15.7%) patients.
The bottom of the targeted tacrolimus trough range was 1-6 ng/ mL across all patients, with the proportional distribution: <3 ng/mL, 3.6% of patients; 3 ng/mL, 20.8%; 4 ng/mL, 57.7%; 5 ng/mL, 16.1%; and 6 ng/mL, 1.2%. The top of the targeted tacrolimus trough range was 3-15 ng/mL across all patients: <5 ng/mL, 2.4%; 5 ng/mL, 10.1%;
6 ng/mL, 37.5%; 7 ng/mL, 20.2%; 8 ng/mL, 19.0%; and >8 ng/mL,
10.7%. Nonadherence was assumed if tacrolimus concentrations were
either below the lower end of the targeted range or >15 ng/mL. Based on these criteria, 75 patients (49.0%) were nonadherent. Of these, 71 (46.4%) had at least one tacrolimus trough level below their predefined minimum concentration. Tacrolimus concentrations >15 ng/ mL were observed in 11 (7.2%) transplant recipients.
T A B L E 1 Composite primary variable
Component Criterion for nonadherence
Patient self-report using the four-item BAASIS questionnaire at V4 1. Do you recall not taking your tacrolimus capsules at any time during the past 4 wk? 2. Have you skipped several consecutive doses of tacrolimus during the past 4 wk? 3. Do you recall taking your tacrolimus capsules more than 2 h from the prescribed dosing time during the past 4 wk? 4. Have you reduced the prescribed amount of your tacrolimus capsules during the past 4 wk?
If any of the questions were answered with "yes" Investigator rating of adherence at V4 considering observations during the past 4 wk A rating of "poor"
Individual tacrolimus trough levels determined (regardless of analytical method used) throughout the observation period:
• Below therapeutic range: lower than individual target trough level set by the investigator • Over therapeutic range: trough levels >15 ng/mL
At least one concentration outside their predefined range BAASIS, Basel Assessment of Adherence with Immunosuppressive Medication Scale; h, hours; V, visit; w, weeks.
The proportion of nonadherent patients was numerically higher in female vs male patients (75.5% vs 67.4%), patients aged <50 vs ≥50 years (80.3% vs 62.5%), recipients of living vs deceased donor organs (78.9% vs 67.3%), and patients with vs without prior rejection episodes (79.5% vs 66.3%) ( Table 5 ). However, due to the small sample size in some subgroups, data should be interpreted with caution.
| Secondary adherence variables
Overall self-reported adherence using BAASIS was 52.3% and 55.1%
at V1 and V4, respectively. For individual BAASIS items at V1 and V4, adherence was lowest for scheduled time (±2 hours) of medication intake (58.2% and 58.3%, respectively) vs ≥86% for all other items ( Figure 1 ). There was no change in mean BAASIS sum score between V1 and V4. Additionally, using the BAASIS VAS, mean (SD) adherence was similar at V1 and V4 (96.1% [6.3] and 96.7% [7. 0], respectively).
Recordings from ProMate were not analyzed, as only three (2.0%) patients opted to use this device.
Adherence was rated as "good" for 84%-92% of patients across visits, and poor for 0%-3%, with only marginal differences between investigator and nurse assessments. At V4, all patients stated that they were either "very satisfied" or "satisfied" with the once-daily dosing regimen and most (94.7% of patients with valid data) considered the prolongedrelease tacrolimus regimen to be more convenient and to facilitate greater adherence than twice-daily tacrolimus administration (Table 6 ).
(Continues) 
| Clinical outcome measures
In two (1.3%) patients, one late acute rejection episode was reported, one of which was classed as calcineurin inhibitor-related nephropathy according to the biopsy result; both patients were considered nonadherent for the composite variable. Graft loss due to fibrosis 10 years post-transplant was recorded for one (0.7%) patient.
Renal function remained stable throughout the 18-month observation period. Mean creatinine clearance, estimated by Cockcroft-Gault, was 62.1 mL/min at V1 (n = 153) and 65.3 mL/min at V4 (n = 127). At V1, creatinine clearance was numerically higher in patients who had received a kidney from a living vs deceased donor and remained numerically higher throughout subsequent visits (V1: 69.1 mL/min vs 60.0 mL/ min, respectively) ( Figure 2 ). During the study, 10 (6.5%) patients required dialysis due to acute kidney injury: eight patients had one dialysis episode, one patient had two episodes, and one patient had three episodes. By end of the study, eight of the 10 patients had stopped dialysis.
Clinically-relevant abnormal urinary protein levels were reported for six (3.9%), eight (5.2%), three (2.0%), and three (2.0%) patients at V1-4, respectively. Clinically-relevant abnormal urinary albumin levels were reported for one (0.7%), four (2.6%), three (2.0%), and two (1.3%) patients, at V1-4, respectively. Investigators assessed the overall effectiveness of prolongedrelease tacrolimus as "very good" or "good" in 91.5% of patients.
| Safety
No death was reported during the observation period. Overall, 15
ADRs were observed in 13 (8.5%) patients, primarily classified as "Infections and Infestations," which included clinical diagnoses of bronchitis (n = 1), endocarditis (n = 1), urinary tract infection (n = 3), and urosepsis (n = 2). Other ADRs (preferred terms) were basal cell carcinoma (n = 2), penile cancer (n = 1), hyperglycemia (n = 1), tremor (n = 2), alopecia (n = 1), and decrease in drug level (n = 1). The causal relationship was considered "probable" for six (40%) and "possible" for nine (60%) of these events. Overall, 11 of these ADRs were considered to be serious, requiring hospitalization. Nonserious ADRs comprised urinary tract infection (n = 1), tremor (n = 1), bronchitis (n = 1), and alopecia (n = 1). At V4, 10 ADRs were rated as recovered without sequelae, three as recovered with sequelae, one as recovering, and for one ADR, outcome was not specified.
Vital signs remained stable during the study. Mean (SD) systolic (10.9) mm Hg (n = 149) and 79.5 (11.0) mm Hg (n = 130), and mean heart rate was 72.6 (11.6) beats/min (n = 148) and 72.7 (10.8) beats/ min (n = 123), at V1 and V4, respectively.
Based on the FAS, physicians rated overall tolerability of prolonged-release tacrolimus as "very good" or "good" for 142 (92.8%) and "moderate" for two (1.3%) patients. For nine (5.9%) patients, no assessment was made. 
T A B L E 3 Prolonged-release tacrolimus dose and trough levels T A B L E 4 Assessment of primary composite variable
Element
Number of patients (%)
Self-reported nonadherence to at least one item of the BAASIS questionnaire at V4 Nonadherence as assessed by a stringent composite endpoint in this long-term German observational study appeared high. Tacrolimus concentrations below the defined lower target levels and BAASIS self-reported nonadherence to timely medication intake (±2 hours from scheduled time) were the primary reasons for the observed outcome. There was little evidence for drug holidays. The overall rate of adherence to the "taking" domain of BAASIS at Visit 4 was high (91.3%) and was consistent with the finding for the prolonged-release tacrolimus dosing group (88.2%) from Kuypers et al. 12 The latter study had enrolled 219 renal transplant recipients (2:1 randomization prolonged-vs immediate-release tacrolimus) and demonstrated significantly improved adherence (P = .0009) to the once-daily dosing regimen. There was also evidence that the evening dose was missed more often than the morning dose, with a mean percentage of missed doses of 14.2% and 11.7%, respectively (P = .0035). Most patients enrolled into our study preferred the convenience of a once-daily dosing regimen (morning dose).
The impact of conversion from a twice-daily to a once-daily tacrolimus regimen on nonadherence was demonstrated in a study including 125 stable liver transplant recipients. Nonadherence as assessed by BAASIS declined from 66.4% (immediate-release tacrolimus) at study entry to 30.9% (prolonged-release tacrolimus) at 1 year postconversion (P < .0001). 15 The mean BAASIS sum score in this study was low and indicative of an acceptable overall adherence to the prescribed dosing regimen. However, most patients who had prior rejection episodes were assessed to be nonadherent (primary variable) during the observation period.
In this study, the nonadherence rate for the composite endpoint was primarily driven by timing (not taking) nonadherence using the BAASIS and tacrolimus trough levels outside a predefined range.
The tacrolimus trough level data should be interpreted with caution.
While intrapatient variability in tacrolimus trough levels has been associated with kidney transplant failure, 16 whether a single tacrolimus trough level outside the predefined range can adversely affect clinical outcomes is unclear. Regarding the BAASIS, higher timing vs taking nonadherence has been reported previously. 15 In line with Kuypers et al, taking nonadherence and nonadherence with administering the correct dosing were low in our study; 12 low nonadherence in these BAASIS parameters may have driven the positive clinical outcomes observed.
Response
Full analysis set, n (%)
Patients receiving first-line prolonged-release tacrolimus, n (%)
Patients converted to prolonged-release tacrolimus, n (%)
How satisfied are you with the once-daily tacrolimus dosing? T A B L E 6 Assessment of patient satisfaction with prolonged-release tacrolimus F I G U R E 2 Mean creatinine clearance over time. SD, standard deviation; V, visit
Patient and graft survival during the 18-month follow-up were 100% and 99.3%, respectively, and the incidence of acute rejection episodes was low (1.3%). This is in line with data reported by Guirado et al in the R-EVOLUTION study, which included a large cohort of renal transplant recipients (n = 1832) who were converted from an immediate-to a prolonged-release tacrolimus-based regimen a mean of 4.9 years post-transplant. Overall, 1496 patients completed the 3-year follow-up; 3-year patient and graft survival rates were high (95.1% and 93.9%, respectively), and rejection rates were low (0.6%, 1.1%, and 0.4% at years 1-3, respectively).
17
Ten patients received dialysis during the 18-month study period;
however, by the end of the study, eight of those 10 patients no longer required dialysis. Renal function as assessed by creatinine clearance Clinical routine practice confirmed the safety and effectiveness of the prolonged-release tacrolimus regimen. This was also reflected in the investigator ratings of these parameters. Tacrolimus levels were generally maintained at the lower end of the therapeutic range and reflected those of recent controlled clinical trials. 12, 18 Limitations of the study include the lack of a control group and the small sample size in the subgroups. Some data were also missing, which is typical of noninterventional studies. Overall adherence was that the patients in this study were low immunologic risk, and the impact of nonadherence might have been more pronounced in a higherrisk population. However, as this was a noninterventional study, the study drug was not provided by the sponsor, but was covered through health insurance, as is usual for post-transplant maintenance care in 
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